Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Laser Vision Centers, Inc. (NASDAQ: LVCI) -- Ignore unavailable to you. Want to Upgrade?

To: James Ratzliff who wrote (131)	4/16/1998 1:17:00 PM
From: Jim Mac	Respond to of 413

Once the analysts realize LVCI will earn $1.00 fully-taxed calendar 1999 (more on a cash basis adding back in dep/amort), and people realize LVCI is doing 1,500 procedures per U.S. laser annualized (3000 per month in March, divided by 23, multiplied by 12 months), I think you'll see LVCI valued closer to LZRCF. LVCI is growing at twice the industry rate, and much faster than LCAV and LZRCF. Every new laser LVCI brings on line breaks even within 2-3 months, vs a year for everyone else. They're generating $1M cash per Q now, and that will rise by $500,000 per Q going forward. LVCI currently doing $6M U.S. revs per Q. Can easily add another $6M per Q to top line next year. They keep 2/3 after procedure fees to Visx, and after taxed, can have roughly $2.5M fully-taxed on bottom line, $3.0M adding back in dep/amort. Hyperopia adds even more to that, as do acquisitions and new contracts.